|
Matinas Biopharma Holdings, Inc. (MTNB) DCF -Bewertung
US | Healthcare | Biotechnology | AMEX
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Matinas BioPharma Holdings, Inc. (MTNB) Bundle
Entdecken Sie den wahren Wert von Matinas Biopharma Holdings, Inc. (MTNB) mit unserem fortschrittlichen DCF -Taschenrechner! Passen Sie die wichtigsten Annahmen an, erkunden Sie verschiedene Szenarien und untersuchen, wie unterschiedliche Variablen die Bewertung von Matinas Biopharma beeinflussen - alles innerhalb einer bequemen Excel -Vorlage.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .1 | .2 | .0 | 3.2 | 1.1 | 1.2 | 1.3 | 1.4 | 1.5 | 1.6 |
| Revenue Growth, % | 0 | 75.93 | -78.95 | 9464.1 | -65.62 | 7.84 | 7.84 | 7.84 | 7.84 | 7.84 |
| EBITDA | -18.6 | -23.9 | -24.5 | -24.2 | -22.8 | -1.2 | -1.3 | -1.4 | -1.5 | -1.6 |
| EBITDA, % | -20658.08 | -15105.21 | -73365.73 | -760.16 | -2082.57 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .8 | .8 | .8 | .9 | .9 | 1.0 | 1.1 | 1.1 | 1.2 | 1.3 |
| Depreciation, % | 867.57 | 489.21 | 2344.5 | 28.17 | 85.86 | 82.81 | 82.81 | 82.81 | 82.81 | 82.81 |
| EBIT | -19.4 | -24.7 | -25.2 | -25.1 | -23.8 | -1.2 | -1.3 | -1.4 | -1.5 | -1.6 |
| EBIT, % | -21525.66 | -15594.42 | -75710.23 | -788.33 | -2168.43 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 27.8 | 58.7 | 49.6 | 28.8 | 13.8 | 1.2 | 1.3 | 1.4 | 1.5 | 1.6 |
| Total Cash, percent | .0 | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payable | .7 | .3 | .9 | .6 | .5 | .9 | .9 | 1.0 | 1.1 | 1.2 |
| Accounts Payable, % | 754.79 | 221.02 | 2811.03 | 19.39 | 46.9 | 73.26 | 73.26 | 73.26 | 73.26 | 73.26 |
| Capital Expenditure | -.4 | .0 | -.3 | -.9 | -.2 | -.6 | -.6 | -.7 | -.7 | -.8 |
| Capital Expenditure, % | -450.67 | -3.63 | -781.15 | -27.98 | -19.89 | -50.3 | -50.3 | -50.3 | -50.3 | -50.3 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -17.4 | -22.7 | -22.9 | -15.6 | -23.8 | -1.0 | -1.1 | -1.2 | -1.3 | -1.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -16.3 | -22.2 | -21.8 | -15.9 | -23.1 | -.3 | -.6 | -.7 | -.7 | -.8 |
| WACC, % | 6.92 | 6.96 | 6.94 | 6.26 | 7.16 | 6.85 | 6.85 | 6.85 | 6.85 | 6.85 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1 | |||||||||
| Terminal Value | -16 | |||||||||
| Present Terminal Value | -12 | |||||||||
| Enterprise Value | -14 | |||||||||
| Net Debt | -1 | |||||||||
| Equity Value | -13 | |||||||||
| Diluted Shares Outstanding, MM | 4 | |||||||||
| Equity Value Per Share | -3.02 |
What You Will Get
- Comprehensive MTNB Financials: Access historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Explore various scenarios to assess Matinas BioPharma's future outlook.
- User-Friendly Interface: Designed for industry experts while remaining approachable for newcomers.
Key Features
- Customizable Clinical Parameters: Adjust essential inputs such as trial success rates, market penetration, and R&D expenses.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional metrics with ease.
- High-Precision Accuracy: Leverages Matinas BioPharma's actual financial data for trustworthy valuation results.
- Effortless Scenario Analysis: Evaluate various assumptions and analyze results without hassle.
- Efficiency Booster: Remove the necessity of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Matinas BioPharma data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Matinas BioPharma’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Matinas BioPharma Holdings, Inc. (MTNB)?
- Innovative Solutions: Cutting-edge biopharmaceutical products designed to improve patient outcomes.
- Proven Expertise: A team of industry professionals committed to advancing healthcare through research and development.
- Strong Pipeline: A diverse range of therapeutic candidates targeting significant unmet medical needs.
- Commitment to Quality: Adherence to the highest standards in manufacturing and clinical practices.
- Investor Confidence: Backed by a solid financial foundation and a strategic vision for growth.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Matinas BioPharma Holdings, Inc. (MTNB) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to Matinas BioPharma Holdings, Inc. (MTNB).
- Consultants: Deliver professional valuation insights regarding Matinas BioPharma Holdings, Inc. (MTNB) to clients quickly and accurately.
- Business Owners: Understand how biopharmaceutical companies like Matinas BioPharma Holdings, Inc. (MTNB) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Matinas BioPharma Holdings, Inc. (MTNB).
What the Template Contains
- Preloaded MTNB Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.